The authors reported long-term follow-up of the Phase Ib study of venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy.
[Blood]
7992332
{7992332:BBBBBBBB}
apa
50
1
166727
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
